Idelalisib in CLL and iNHL

February 25, 2014
Anas Younes, MD

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses treatment with idelalisib for chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin lymphoma (iNHL)

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses treatment with idelalisib for chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin lymphoma (iNHL).

Clinical Pearls:

  • Idelalisib is a PI3K-delta-specific inhibitor
  • Idelalisib demonstrated promising results in various trials in CLL and iNHL
  • Idelalisib has little side effects, is very well tolerated, and improves quality of life